ArticleFrontiers in oncology2026
Perioperative management of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a patient with moyamoya disease: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Moyamoya disease (MMD) is a rare chronic occlusive cerebrovascular disorder associated with a high risk of perioperative ischemic or hemorrhagic stroke. Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive system tumor with high surgical risk. The coexistence of MMD and PDAC is extremely rare, and no consensus on standardized perioperative management protocols has been established to date. The core clinical challenge lies in balancing the goal of radical tumor resection against the prevention of potentially devastating perioperative cerebrovascular events. Case presentation: A 62-year-old Asian man with a 5-year history of asymptomatic MMD (managed with aspirin 100 mg daily) presented with painless obstructive jaundice and 5-kg unintentional weight loss. Imaging examinations demonstrated a 1.5 × 1.4 cm nodular lesion in the pancreatic head, which involved the intramural segment of the common bile duct and the duodenum. The preliminary diagnosis was pancreatic cancer. Cerebral computed tomography perfusion (CTP) showed compensatory cerebral blood volume elevation with a focal ischemic penumbra. The disease was classified as Suzuki stage III. Management and outcomes: A multidisciplinary team (MDT) formulated an individualized perioperative strategy: (1) strict hemodynamic regulation with mean arterial pressure (MAP) maintained at 80-100 mmHg, (2) optimized anesthesia with continuous regional cerebral oxygen saturation (rSO2) monitoring, and (3) staged balanced anticoagulation with low-molecular-weight heparin (LMWH) bridging. The patient underwent standard pancreaticoduodenectomy (PD). The patient had an uneventful perioperative course, with no cerebrovascular events or major surgical complications. The final pathological examination confirmed moderately differentiated PDAC (pT1cN0M0, AJCC 8th edition) with R0 resection. During postoperative follow-up, the patient exhibited no tumor recurrence, neurological deficits, or cerebrovascular events. Conclusion: For patients with MMD undergoing radical PD, MDT-guided individualized management centered on cerebral perfusion maintenance, hemodynamic stability, and staged anticoagulation may help mitigate perioperative risks and achieve favorable clinical outcomes. This case provides practical experience for clinicians confronted with similarly rare clinical conditions. Given the inherent limitations of a single-case design, its generalizability remains to be validated in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.